Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Subscribe To Our Newsletter & Stay Updated
